Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
62
datasets available to search
ShareScore release 0.7.1
Dataset results
62 results for “Adverse Drug Reaction”
Adverse Drug Reaction (ADR) Text Dataset
<p>This repository contains text data and code related to the identification and clustering of Adverse Drug Reactions (ADR) using Sentence-BERT (S-BERT) embeddings and the SS-DBSCAN clustering algorithm. The dataset includes both labeled and unlabeled patient reports extracted from the publicly available MIMIC-III database.</p> <p>The labeled data has been manually annotated to distinguish between ADR and non-ADR cases. The unlabeled dataset is used for unsupervised clustering experiments, particularly to assess high-dimensional data clustering performance.</p> <p>New in This Version:<br>- Added Jupyter Notebook: `mimic-5k_PCA_tSNE_clustering.ipynb`<br>- Included detailed `README_ADR_Clustering_Task.txt` with step-by-step instructions to reproduce clustering results<br>- Explained how to scale experiments from 1,000 to full dataset size</p>
A novel preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs - Supplementary Material
<p>All Supplementary materials and source data for the manuscript.</p> <p>The reported analyses and results can be reproduced via the described IPython notebooks which can be found under www.github.com/Novartis/SPD</p>
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
ClinicalTrials.gov study NCT01276314. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)
ClinicalTrials.gov study NCT05667766. IPD Sharing: YES. Countries: 1. Publications: 1.
The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
ClinicalTrials.gov study NCT03955133. IPD Sharing: NO. Countries: 1. Publications: 3.
supplementary data for Genetic Polymorphism on Olanzapine-Induced Adverse Drug Reaction in Schizophrenic Patients
<p>this file contain supplementary data including age gender .... for our research </p>
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
ClinicalTrials.gov study NCT05307718. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs
ClinicalTrials.gov study NCT00979290. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Adverse Drug Reactions in Older Subjects
ClinicalTrials.gov study NCT03623542. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
ClinicalTrials.gov study NCT03492242. IPD Sharing: UNDECIDED. Countries: 1. Publications: 12.
E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT03029897. IPD Sharing: NO. Countries: 1. Publications: 2.
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
ClinicalTrials.gov study NCT03093818. IPD Sharing: YES. Countries: 7. Publications: 4.
HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions
ClinicalTrials.gov study NCT03184597. IPD Sharing: YES. Countries: 1. Publications: 7.
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
ClinicalTrials.gov study NCT04154553. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.
ClinicalTrials.gov study NCT03678337. IPD Sharing: NO. Countries: 1. Publications: 1.
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
ClinicalTrials.gov study NCT00414115. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Diagnosing Adverse Drug Reactions Registry
ClinicalTrials.gov study NCT01970709. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Serious Adverse Drug Reaction and Their Preventability
ClinicalTrials.gov study NCT02888834. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Figure 3 from: Ali ZJM, Al-juhiashi AMR (2024) Role of D2 receptor (–141 C Ins/Del) genetic polymorphism on olanzapine-induced adverse drug reaction in schizophrenic patients. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e112064
Figure 3 The Prevalence of D2 receptor alleles rs1799732 (141c ins/del) among both male and female volunteers.
Adverse drug reactions to the three doses of the SARS-COV-2 mRNA-1273 vaccine in a cohort of cancer patients of a tertiary hospital
<p><strong>Introduction:</strong> SARS-CoV-2 vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or underrepresented. Information is scarce regarding safety in this population. </p> <p><strong>Methods:</strong> The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This cross sectional study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect tha available information in 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study.</p> <p><strong>Results:</strong> 93 patients met inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs were reported less frequently after the first and second dose than after the third (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with higher ECOG score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that females had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016).</p> <p><strong>Conclusion:</strong> mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.<span></span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.